Menu
Search
|

Menu

Close
X

Cancer Genetics Inc CGIX.OQ (NASDAQ Stock Exchange Capital Market)

1.75 USD
-0.05 (-2.78%)
As of 2:29 AM IST
chart
Previous Close 1.80
Open 1.80
Volume 16,490
3m Avg Volume 32,221
Today’s High 1.80
Today’s Low 1.70
52 Week High 5.25
52 Week Low 1.58
Shares Outstanding (mil) 19.79
Market Capitalization (mil) 53.93
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.75 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY17
22
FY16
27
FY15
18
EPS (USD)
FY17
-0.677
FY16
-1.039
FY15
-1.964
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
1.96
5.77
Price to Book (MRQ)
vs sector
2.89
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
41.81
16.52
LT Debt to Equity (MRQ)
vs sector
29.66
12.22
Return on Investment (TTM)
vs sector
-57.22
14.43
Return on Equity (TTM)
vs sector
-78.97
16.13

EXECUTIVE LEADERSHIP

John Pappajohn
Non-Executive Chairman of the Board, Since 2014
Salary: --
Bonus: --
John Roberts
Interim Chief Executive Officer, Chief Financial Officer, Principal Financial Officer, Since 2018
Salary: --
Bonus: --
Igor Gitelman
Chief Accounting Officer, Principal Accounting Officer, Since 2017
Salary: --
Bonus: --
Rita Shaknovich
Medical Director, Vice President - Hematopathology Services, Since 2015
Salary: --
Bonus: --
Jane Houldsworth
Vice President - Research & Development, Since 2011
Salary: $275,192.00
Bonus: $26,500.00

COMPANY PROFILE

Sector: Healthcare
Industry: Healthcare Facilities & Services
Address:

201 State Rt 17 Fl 2
RUTHERFORD   NJ   07070-2597

Phone: +1201.5289200

Cancer Genetics, Inc. is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide genomic and biomarker information. Its Select One Clinical Trials program provides a range of integrated and dynamic clinical trial services for both oncology and non-oncology genetic testing for Phase I-III trials along with ancillary services, including bioinformatics, biorepository and trials logistic support. The Company is developing a global footprint with locations in the United States, India and China. It also offers a portfolio of genotyping services, with access to over 400 validated genotyping assays, including Phase I and Phase II drug metabolizing enzymes, transporters, and receptors, and over 30 validated gene expression assays.

SPONSORED STORIES